Qin Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qin Luo has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Zhihong Liu
Center for Respiratory and Pulmonary Vascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
37 shared publications Zhihui Zhao
Center for Respiratory and Pulmonary Vascular Diseases, Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 100037 Beijing, China
27 shared publicationsAnqi Duan
Center for Respiratory and Pulmonary Vascular Diseases, Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 100037 Beijing, China
26 shared publicationsQing Zhao
Center for Respiratory and Pulmonary Vascular Diseases, Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 100037 Beijing, China
26 shared publicationsXin Li
Center for Respiratory and Pulmonary Vascular Diseases, Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 100037 Beijing, China
23 shared publicationsZhihua Huang
Center for Respiratory and Pulmonary Vascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
20 shared publications
Latest Publications
- Open Access
- 28 July 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (7)
Cardiovascular Disease, Sleep-Disordered Breathing, and Artificial Intelligence: From Neutral Trials to Precision Sleep Cardiology
Sleep-disordered breathing (SDB), which includes both obstructive and central sleep apnea, is highly prevalent among patients with cardiovascular disease (CVD). Moreover, SDB contributes significantly to the development and progression of hypertension, coronary artery disease, arrhythmias, heart failure, and various cardiovascular and cerebrovascular events. However, despite strong mechanistic links involving intermittent hypoxemia, sympathetic activation, intrathoracic pressure fluctuations, and systemic inflammation, clinical trials of SDB treatment have yielded in neutral or even adverse cardiovascular outcomes. These results underscore the need for refined phenotyping, risk stratification, and personalized management. Artificial intelligence (AI) has emerged as a promising tool to address these challenges. In this review, we evaluate the mechanistic pathways through which SDB affects cardiovascular health and critically examine AI-based methods to enhance screening, outcome prediction, and treatment optimization. Applications include automated detection using clinical and biosignal data, cardiovascular risk prediction through machine-learning models based on sleep parameters, and AI-guided therapy personalization. Furthermore, we emphasize translational relevance by comparing model performance, identifying high-risk phenotypes, and exploring the potential for integration into clinical workflows. AI-enabled tools may help bridge the gap between pathophysiological understanding and improved outcomes by facilitating earlier diagnosis, tailored interventions, and proactive monitoring. Future studies should focus on prospective validation, regulatory pathways, and equitable deployment across populations.
- 28 July 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (7)
Open AccessCardiovascular Disease, Sleep-Disordered Breathing, and Artificial Intelligence: From Neutral Trials to Precision Sleep Cardiology
Sleep-disordered breathing (SDB), which includes both obstructive and central sleep apnea, is highly prevalent among patients with cardiovascular disease (CVD). Moreover, SDB contributes significantly to the development and progression of hypertension, coronary artery disease, arrhythmias, heart failure, and various cardiovascular and cerebrovascular events. However, despite strong mechanistic links involving intermittent hypoxemia, sympathetic activation, intrathoracic pressure fluctuations, and systemic inflammation, clinical trials of SDB treatment have yielded in neutral or even adverse cardiovascular outcomes. These results underscore the need for refined phenotyping, risk stratification, and personalized management. Artificial intelligence (AI) has emerged as a promising tool to address these challenges. In this review, we evaluate the mechanistic pathways through which SDB affects cardiovascular health and critically examine AI-based methods to enhance screening, outcome prediction, and treatment optimization. Applications include automated detection using clinical and biosignal data, cardiovascular risk prediction through machine-learning models based on sleep parameters, and AI-guided therapy personalization. Furthermore, we emphasize translational relevance by comparing model performance, identifying high-risk phenotypes, and exploring the potential for integration into clinical workflows. AI-enabled tools may help bridge the gap between pathophysiological understanding and improved outcomes by facilitating earlier diagnosis, tailored interventions, and proactive monitoring. Future studies should focus on prospective validation, regulatory pathways, and equitable deployment across populations.
- Open Access
Retrospective Evaluation of Recombinant Human Brain Natriuretic Peptide Therapy for Decompensated Right Heart Failure Across Pulmonary Hypertension Groups
Background and Objectives: Right heart failure is a life-threatening complication of pulmonary hypertension (PH), with limited treatment options. Although recombinant human brain natriuretic peptide (rhBNP) is widely used in left heart failure, its effectiveness in right heart failure associated with varying groups of PH (Groups 1, 2, and 4) is unknown. Materials and Methods: 763 patients with varying groups of PH (PH Groups 1, 2, and 4) were enrolled and received both conventional therapy and rhBNP treatment. Therapeutic efficacy and adverse event incidence were evaluated among the PH groups. Results: Significant reductions in variables reflecting cardiac congestion, including NT-proBNP, total bilirubin, and body weight, were observed in all PH subgroups (all p < 0.001). The median percentage changes were −47% (IQR −76 to −24), −21% (IQR −33 to −1), and −3% (IQR −7 to −1), respectively. Alanine transaminase levels presented a decreasing trend (p < 0.001), whereas creatinine levels remained unchanged (p > 0.05), with consistent trends across PH subgroups. The hemodynamic response was heterogeneous, with marked decreases in the mean arterial pressure in Groups 1 and 4 (p < 0.001) but not in Group 2. Improvement in dyspnea and edema of the lower limbs was observed in 49.9% and 66.6% of cases, respectively. The overall incidence of adverse events was 0.66%, with 0.26% (2/763) being serious, all of which were in Group 1 PH. Conclusions: Findings from this exploratory analysis indicated that rhBNP treatment was associated with favorable changes in congestive status and clinical symptoms across different PH subgroups, as well as stable end-organ function. Of note, all patients received comprehensive conventional background therapy; thus, these improvements cannot be exclusively attributed to rhBNP alone. Given the observed hemodynamic fluctuations, close blood pressure monitoring should be considered throughout the treatment course, particularly for patients in Groups 1 and 4, and most notably for high-risk PAH patients (Group 1 PH).
Open AccessRetrospective Evaluation of Recombinant Human Brain Natriuretic Peptide Therapy for Decompensated Right Heart Failure Across Pulmonary Hypertension Groups
Background and Objectives: Right heart failure is a life-threatening complication of pulmonary hypertension (PH), with limited treatment options. Although recombinant human brain natriuretic peptide (rhBNP) is widely used in left heart failure, its effectiveness in right heart failure associated with varying groups of PH (Groups 1, 2, and 4) is unknown. Materials and Methods: 763 patients with varying groups of PH (PH Groups 1, 2, and 4) were enrolled and received both conventional therapy and rhBNP treatment. Therapeutic efficacy and adverse event incidence were evaluated among the PH groups. Results: Significant reductions in variables reflecting cardiac congestion, including NT-proBNP, total bilirubin, and body weight, were observed in all PH subgroups (all p < 0.001). The median percentage changes were −47% (IQR −76 to −24), −21% (IQR −33 to −1), and −3% (IQR −7 to −1), respectively. Alanine transaminase levels presented a decreasing trend (p < 0.001), whereas creatinine levels remained unchanged (p > 0.05), with consistent trends across PH subgroups. The hemodynamic response was heterogeneous, with marked decreases in the mean arterial pressure in Groups 1 and 4 (p < 0.001) but not in Group 2. Improvement in dyspnea and edema of the lower limbs was observed in 49.9% and 66.6% of cases, respectively. The overall incidence of adverse events was 0.66%, with 0.26% (2/763) being serious, all of which were in Group 1 PH. Conclusions: Findings from this exploratory analysis indicated that rhBNP treatment was associated with favorable changes in congestive status and clinical symptoms across different PH subgroups, as well as stable end-organ function. Of note, all patients received comprehensive conventional background therapy; thus, these improvements cannot be exclusively attributed to rhBNP alone. Given the observed hemodynamic fluctuations, close blood pressure monitoring should be considered throughout the treatment course, particularly for patients in Groups 1 and 4, and most notably for high-risk PAH patients (Group 1 PH).
- Open Access
- 2 December 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (12) , e70426
Impact of Stress Hyperglycemia Ratio on Adverse Outcomes in Patients With Chronic Thromboembolic Pulmonary Hypertension
Prognostic assessment of chronic thromboembolic pulmonary hypertension (CTEPH) remains challenging. Stress hyperglycemia, a condition where glucose metabolism is regulated during stress, has been regarded as an indicator of acute hyperglycemia. The stress hyperglycemia ratio (SHR) serves as a more precise marker for this state. This research intended to investigate the prognostic function of SHR in CTEPH, as its link to poor outcomes is uncertain. Clinical deterioration events were the primary endpoint. LASSO regression was utilized for variable selection and dimensionality reduction to identify key features and mitigate overfitting. Kaplan–Meier analysis, multivariable Cox regression, and restricted cubic splines were primarily used to investigate the link between SHR and adverse clinical outcomes. Internal validation was performed using bootstrap resampling. Sensitivity analysis was performed to assess the robustness of the findings. The study included a sum of 451 patients with CTEPH; over a median follow‐up of 21 months, 89 (19.7%) patients encountered adverse outcomes. Kaplan–Meier analysis indicated that patients having elevated SHR levels exhibited a markedly higher overall incidence of adverse events. Restricted cubic spline analysis showed a linear relationship between SHR and adverse events. Multivariable Cox regression analysis indicated that higher SHR independently predicts adverse outcomes, whether treated as continuous (hazard ratio, 1.541; 95% confidence interval, 1.252–1.896, p < 0.001) or categorical (hazard ratio, 2.419; 95% confidence interval, 1.268–4.616, p = 0.007). Internal validation demonstrated that the original C‐index was 0.693, with a bias‐corrected C‐index of 0.675 after bootstrap validation. In patients with CTEPH, higher SHR is independently associated with clinical worsening. The prognostic significance of SHR remained robust across internal validation and multiple sensitivity analyses.
- 2 December 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (12) , e70426
Open AccessImpact of Stress Hyperglycemia Ratio on Adverse Outcomes in Patients With Chronic Thromboembolic Pulmonary Hypertension
Prognostic assessment of chronic thromboembolic pulmonary hypertension (CTEPH) remains challenging. Stress hyperglycemia, a condition where glucose metabolism is regulated during stress, has been regarded as an indicator of acute hyperglycemia. The stress hyperglycemia ratio (SHR) serves as a more precise marker for this state. This research intended to investigate the prognostic function of SHR in CTEPH, as its link to poor outcomes is uncertain. Clinical deterioration events were the primary endpoint. LASSO regression was utilized for variable selection and dimensionality reduction to identify key features and mitigate overfitting. Kaplan–Meier analysis, multivariable Cox regression, and restricted cubic splines were primarily used to investigate the link between SHR and adverse clinical outcomes. Internal validation was performed using bootstrap resampling. Sensitivity analysis was performed to assess the robustness of the findings. The study included a sum of 451 patients with CTEPH; over a median follow‐up of 21 months, 89 (19.7%) patients encountered adverse outcomes. Kaplan–Meier analysis indicated that patients having elevated SHR levels exhibited a markedly higher overall incidence of adverse events. Restricted cubic spline analysis showed a linear relationship between SHR and adverse events. Multivariable Cox regression analysis indicated that higher SHR independently predicts adverse outcomes, whether treated as continuous (hazard ratio, 1.541; 95% confidence interval, 1.252–1.896, p < 0.001) or categorical (hazard ratio, 2.419; 95% confidence interval, 1.268–4.616, p = 0.007). Internal validation demonstrated that the original C‐index was 0.693, with a bias‐corrected C‐index of 0.675 after bootstrap validation. In patients with CTEPH, higher SHR is independently associated with clinical worsening. The prognostic significance of SHR remained robust across internal validation and multiple sensitivity analyses.
- Open Access
- 7 November 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-2
Correction: Is pulmonary vascular remodeling an intermediate link between hyperglycemia and adverse outcomes in patients with idiopathic pulmonary arterial hypertension? Insights from a multi-center cohort study
- 7 November 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-2
Open AccessCorrection: Is pulmonary vascular remodeling an intermediate link between hyperglycemia and adverse outcomes in patients with idiopathic pulmonary arterial hypertension? Insights from a multi-center cohort study
- Open Access
- 3 June 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (11) , e039343
Association of Ambient Air Pollution With Invasive Pulmonary Hemodynamics and Long‐Term Outcomes in Patients With Pulmonary Arterial Hypertension
Background: Although the impact of ambient air pollution on mortality in cardiovascular and pulmonary diseases is well documented, its specific link to pulmonary arterial hypertension remains unclear. This study investigated the association between ambient particulate matter (PM) exposure and all‐cause death or lung transplantation, as well as pulmonary hemodynamics in patients with pulmonary arterial hypertension. Methods: This retrospective cohort study included 1327 participants with pulmonary arterial hypertension who underwent right heart catheterization (RHC). Ambient PM 2.5 and PM 10 levels were estimated using the China High Air Pollutants data set, with a 3‐year average exposure before diagnosis as the primary exposure metric. All‐cause death or lung transplantation was the primary end point. Cox proportional hazard models assessed the association between PM exposure and primary outcomes, and generalized linear models evaluated pulmonary hemodynamics. Mediation analysis explored potential mediating factors. Results: The median age of the participants was 33.0 years, with 73.2% being women. Median PM 2.5 and PM 10 levels were 58.0 [43.6‐76.1] and 103.0 [80.4‐129.3] μg/m 3 , respectively. Over a median follow‐up of 3.1 years, 149 patients died or underwent lung transplantation. Each 10 μg/m 3 increase in PM 2.5 and PM 10 was associated with a 14.5% and 7.9% increased risk of primary outcomes, respectively. PM exposure was linked to worsened pulmonary hemodynamics, such as pulmonary vascular resistance and cardiac index. Mediation analysis suggested lipid metabolism, uric acid, and lymphocytes may partially mediate these effects. Conclusions: Long‐term PM 2.5 and PM 10 exposure is not only associated with increased risk of death or lung transplantation in patients with pulmonary arterial hypertension but also affects disease severity and pulmonary hemodynamics.
- 3 June 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (11) , e039343
Open AccessAssociation of Ambient Air Pollution With Invasive Pulmonary Hemodynamics and Long‐Term Outcomes in Patients With Pulmonary Arterial Hypertension
Background: Although the impact of ambient air pollution on mortality in cardiovascular and pulmonary diseases is well documented, its specific link to pulmonary arterial hypertension remains unclear. This study investigated the association between ambient particulate matter (PM) exposure and all‐cause death or lung transplantation, as well as pulmonary hemodynamics in patients with pulmonary arterial hypertension. Methods: This retrospective cohort study included 1327 participants with pulmonary arterial hypertension who underwent right heart catheterization (RHC). Ambient PM 2.5 and PM 10 levels were estimated using the China High Air Pollutants data set, with a 3‐year average exposure before diagnosis as the primary exposure metric. All‐cause death or lung transplantation was the primary end point. Cox proportional hazard models assessed the association between PM exposure and primary outcomes, and generalized linear models evaluated pulmonary hemodynamics. Mediation analysis explored potential mediating factors. Results: The median age of the participants was 33.0 years, with 73.2% being women. Median PM 2.5 and PM 10 levels were 58.0 [43.6‐76.1] and 103.0 [80.4‐129.3] μg/m 3 , respectively. Over a median follow‐up of 3.1 years, 149 patients died or underwent lung transplantation. Each 10 μg/m 3 increase in PM 2.5 and PM 10 was associated with a 14.5% and 7.9% increased risk of primary outcomes, respectively. PM exposure was linked to worsened pulmonary hemodynamics, such as pulmonary vascular resistance and cardiac index. Mediation analysis suggested lipid metabolism, uric acid, and lymphocytes may partially mediate these effects. Conclusions: Long‐term PM 2.5 and PM 10 exposure is not only associated with increased risk of death or lung transplantation in patients with pulmonary arterial hypertension but also affects disease severity and pulmonary hemodynamics.
- Open Access
- 1 June 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 8217-8231
Association of Systemic Inflammatory Response Index with Disease Severity and Adverse Outcome in Chronic Thromboembolic Pulmonary Hypertension
Background: Composite inflammatory markers, such as the systemic inflammatory response index (SIRI), are associated with the severity and progression of several cardiovascular diseases. However, the relationship between SIRI and chronic thromboembolic pulmonary hypertension (CTEPH) remains unclear. We hypothesized that elevated SIRI levels would correlate with disease severity and independently predict adverse clinical outcomes in patients with CTEPH. This study aimed to clarify the predictive value of SIRI in patients with CTEPH. Methods: This retrospective cohort study included 383 patients with CTEPH treated at Fuwai Hospital between June 2013 and June 2021. Receiver operating characteristic (ROC) curve analysis was used to compare the diagnostic performance of SIRI to other inflammatory indices and identify the optimal cutoff value. Kaplan-Meier analysis and Cox proportional hazard models were used to examine the relationship between SIRI and clinical worsening. Results: During a mean follow-up period of 30.6 months, 79 participants experienced clinical worsening. The SIRI was significantly correlated with established markers of CTEPH severity, including the 6-minute walk distance, N-terminal pro-brain natriuretic peptide, and hemodynamic parameters. Kaplan–Meier curve revealed that individuals with a SIRI ≥ 0.80 exhibited significantly poorer survival rates and a shorter time to clinical worsening compared to those with a SIRI < 0.80 (P < 0.01). Adjusted Cox proportional hazards analysis revealed that SIRI remained an independent predictor of clinical worsening (hazard ratio (HR) 2.033; 95% confidence interval (CI) 1.227– 3.370). ROC analysis revealed that SIRI exhibited the highest area under the curve value of 0.730 (95% CI 0.659– 0.810). Incorporating SIRI into The COMPERA 2.0, the risk score improved its predictive value for adverse outcomes in patients with CTEPH. Conclusion: SIRI is a valuable prognostic marker for CTEPH, correlating with established markers of disease severity and independently predicting clinical worsening. SIRI provides additional prognostic predictive value when used in conjunction with the risk score of COMPERA 2.0.
- 1 June 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 8217-8231
Open AccessAssociation of Systemic Inflammatory Response Index with Disease Severity and Adverse Outcome in Chronic Thromboembolic Pulmonary Hypertension
Background: Composite inflammatory markers, such as the systemic inflammatory response index (SIRI), are associated with the severity and progression of several cardiovascular diseases. However, the relationship between SIRI and chronic thromboembolic pulmonary hypertension (CTEPH) remains unclear. We hypothesized that elevated SIRI levels would correlate with disease severity and independently predict adverse clinical outcomes in patients with CTEPH. This study aimed to clarify the predictive value of SIRI in patients with CTEPH. Methods: This retrospective cohort study included 383 patients with CTEPH treated at Fuwai Hospital between June 2013 and June 2021. Receiver operating characteristic (ROC) curve analysis was used to compare the diagnostic performance of SIRI to other inflammatory indices and identify the optimal cutoff value. Kaplan-Meier analysis and Cox proportional hazard models were used to examine the relationship between SIRI and clinical worsening. Results: During a mean follow-up period of 30.6 months, 79 participants experienced clinical worsening. The SIRI was significantly correlated with established markers of CTEPH severity, including the 6-minute walk distance, N-terminal pro-brain natriuretic peptide, and hemodynamic parameters. Kaplan–Meier curve revealed that individuals with a SIRI ≥ 0.80 exhibited significantly poorer survival rates and a shorter time to clinical worsening compared to those with a SIRI < 0.80 (P < 0.01). Adjusted Cox proportional hazards analysis revealed that SIRI remained an independent predictor of clinical worsening (hazard ratio (HR) 2.033; 95% confidence interval (CI) 1.227– 3.370). ROC analysis revealed that SIRI exhibited the highest area under the curve value of 0.730 (95% CI 0.659– 0.810). Incorporating SIRI into The COMPERA 2.0, the risk score improved its predictive value for adverse outcomes in patients with CTEPH. Conclusion: SIRI is a valuable prognostic marker for CTEPH, correlating with established markers of disease severity and independently predicting clinical worsening. SIRI provides additional prognostic predictive value when used in conjunction with the risk score of COMPERA 2.0.
- Open Access
- 10 April 2025
- Published by Springer Nature in npj Digital Medicine
- Vol. 8 (1) , 1-11
Development and validation of multimodal deep learning algorithms for detecting pulmonary hypertension
Transthoracic echocardiography (TTE), commonly used for initial screening of pulmonary hypertension (PH), often lacks sufficient accuracy. To address this gap, we developed and validated a multimodal fusion model for improved PH screening (MMF-PH). The study was registered in the ClinicalTrials.gov (NCT05566002, 09/30/2022). The MMF-PH underwent extensive training, validation, and testing, including comparisons with TTE and evaluations across various patient subgroups to assess robustness and reliability. We analyzed 2451 patients who underwent right heart catheterization, supplemented by a prospective dataset of 477 patients and an external dataset. The MMF-PH demonstrated robust performance across different datasets. The model outperformed TTE in terms of specificity and negative predictive value across all test datasets. An ablation study using the external test dataset confirmed the essential role of each module in the MMF-PH. The MMF-PH significantly advances PH detection, offering robust and reliable diagnostic accuracy across diverse patient populations and clinical settings.
- 10 April 2025
- Published by Springer Nature in npj Digital Medicine
- Vol. 8 (1) , 1-11
Open AccessDevelopment and validation of multimodal deep learning algorithms for detecting pulmonary hypertension
Transthoracic echocardiography (TTE), commonly used for initial screening of pulmonary hypertension (PH), often lacks sufficient accuracy. To address this gap, we developed and validated a multimodal fusion model for improved PH screening (MMF-PH). The study was registered in the ClinicalTrials.gov (NCT05566002, 09/30/2022). The MMF-PH underwent extensive training, validation, and testing, including comparisons with TTE and evaluations across various patient subgroups to assess robustness and reliability. We analyzed 2451 patients who underwent right heart catheterization, supplemented by a prospective dataset of 477 patients and an external dataset. The MMF-PH demonstrated robust performance across different datasets. The model outperformed TTE in terms of specificity and negative predictive value across all test datasets. An ablation study using the external test dataset confirmed the essential role of each module in the MMF-PH. The MMF-PH significantly advances PH detection, offering robust and reliable diagnostic accuracy across diverse patient populations and clinical settings.
- Open Access
- 19 February 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-14
Association of insulin resistance surrogates with disease severity and adverse outcomes in chronic thromboembolic pulmonary hypertension: a multicenter cohort study
Chronic thromboembolic pulmonary hypertension (CTEPH) is a severely progressive disease that leads to right heart failure and death. Previous studies have shown that diabetes and insulin resistance (IR) are closely related to pulmonary hypertension, but the role of IR in patients with CTEPH remains unexplored. In this study, we investigated the relationship between four insulin resistance indices and disease severity, hemodynamic parameters, and adverse outcomes in patients with CTEPH. We conducted a multicenter, retrospective cohort study involving 516 patients diagnosed with CTEPH between January 2013 and December 2022. The metabolic score for IR (METS-IR), triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio, triglyceride and glucose (TyG) index, and triglyceride-glucose-body mass (TyG-BMI) index were used to quantify IR levels in patients with CTEPH. The primary endpoint events were clinical worsening. Multivariable Cox regression, restricted cubic splines, and receiver operating characteristic analyses were used to evaluate the predictive value of surrogates for IR. Compared with in low to intermediate-low risk patients, the METS-IR (36.2 ± 6.7 vs. 37.7 ± 8.7, p = 0.038) and TyG-BMI index (204.0 ± 36.2 vs. 212.6 ± 46.5, p = 0.022) were significantly increased in high to intermediate-high risk patients. METS-IR correlated with markers of disease severity, such as World Health Organization functional class, 6-minute walk distance, and N-terminal pro-brain natriuretic peptide levels. During a mean of 2.5 years’ follow-up, 110 participants experienced all-cause death or worsening condition. METS-IR independently predicted clinical worsening (hazard ratio: 1.27; 95% confidence interval 1.06–1.53 per 1.0-standard deviation increment, p = 0.009) after fully adjusting for covariates. Adding METS-IR to the COMPERA 2.0 risk score significantly improved its predictive ability, reclassification and discrimination ability. METS-IR is an independent predictor of clinical worsening in patients with CTEPH. It offers a convenient marker for assessing disease severity and long-term outcomes in clinical risk assessment.
- 19 February 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-14
Open AccessAssociation of insulin resistance surrogates with disease severity and adverse outcomes in chronic thromboembolic pulmonary hypertension: a multicenter cohort study
Chronic thromboembolic pulmonary hypertension (CTEPH) is a severely progressive disease that leads to right heart failure and death. Previous studies have shown that diabetes and insulin resistance (IR) are closely related to pulmonary hypertension, but the role of IR in patients with CTEPH remains unexplored. In this study, we investigated the relationship between four insulin resistance indices and disease severity, hemodynamic parameters, and adverse outcomes in patients with CTEPH. We conducted a multicenter, retrospective cohort study involving 516 patients diagnosed with CTEPH between January 2013 and December 2022. The metabolic score for IR (METS-IR), triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio, triglyceride and glucose (TyG) index, and triglyceride-glucose-body mass (TyG-BMI) index were used to quantify IR levels in patients with CTEPH. The primary endpoint events were clinical worsening. Multivariable Cox regression, restricted cubic splines, and receiver operating characteristic analyses were used to evaluate the predictive value of surrogates for IR. Compared with in low to intermediate-low risk patients, the METS-IR (36.2 ± 6.7 vs. 37.7 ± 8.7, p = 0.038) and TyG-BMI index (204.0 ± 36.2 vs. 212.6 ± 46.5, p = 0.022) were significantly increased in high to intermediate-high risk patients. METS-IR correlated with markers of disease severity, such as World Health Organization functional class, 6-minute walk distance, and N-terminal pro-brain natriuretic peptide levels. During a mean of 2.5 years’ follow-up, 110 participants experienced all-cause death or worsening condition. METS-IR independently predicted clinical worsening (hazard ratio: 1.27; 95% confidence interval 1.06–1.53 per 1.0-standard deviation increment, p = 0.009) after fully adjusting for covariates. Adding METS-IR to the COMPERA 2.0 risk score significantly improved its predictive ability, reclassification and discrimination ability. METS-IR is an independent predictor of clinical worsening in patients with CTEPH. It offers a convenient marker for assessing disease severity and long-term outcomes in clinical risk assessment.